Big Gain For Ocugen, Inc.
Ocugen, Inc. (OCGN:NASDAQ) shot up at $0.4, a gain of 61.3%. On Mon 20 Jul 20, OCGN:NASDAQ hit a New 2-Week High of $0.25. From Mon 06 Jul 20, the stock recorded 30.00% Up Days and 18.18% Green Days
The share price of the company has been moving sideways in recent weeks.
About Ocugen, Inc. (OCGN:NASDAQ)
Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).
Top 10 Gainers:
- Midatech Pharma plc (MTP:NASDAQ), 152.94%
- Owens & Minor, Inc. (OMI:NYSE), 81.36%
- Novan, Inc. (NOVN:NASDAQ), 78.26%
- Ocugen, Inc. (OCGN:NASDAQ), 61.25%
- Tellurian Inc. (TELL:NASDAQ), 56.44%
- New Concept Energy, Inc. (GBR:NYSEMKT), 47.01%
- Immuron Limited (IMRN:NASDAQ), 42.27%
- DelMar Pharmaceuticals, Inc. (DMPI:NASDAQ), 41.5%
- New Age Beverages Corporation (NBEV:NASDAQ), 41.38%
- Independence Contract Drilling, Inc. (ICD:NYSE), 34.57%